---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-150435"
form_type: "8-K"
ticker: "XOMA"
cik: "0000791908"
company_name: "XOMA Royalty Corp"
filed_at: "2024-05-30T23:59:59+00:00"
generated_at: "2026-06-01T07:32:24.404662+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# XOMA to receive $8.1M from Viracta after Day One sells PRV for $108M

## Summary
- Day One Biopharmaceuticals sold a priority review voucher for $108M after FDA approval of OJEMDA.
- XOMA is entitled to $8.1M from Viracta under a March 2021 agreement covering tovorafenib milestones.
- The PRV sale proceeds trigger event-based economics payable to XOMA.
- Funds represent a portion of the PRV proceeds passed through from Day One to Viracta.

## SEC filing metadata
- accession: 0001193125-24-150435
- form_type: 8-K
- ticker: XOMA
- cik: 0000791908
- company_name: XOMA Royalty Corp
- filed_at: 2024-05-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/791908/000119312524150435/0001193125-24-150435-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/791908/000119312524150435/d839143d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-150435
- JSON: https://secwatch.observer/filing/0001193125-24-150435.json
- Plain text: https://secwatch.observer/filing/0001193125-24-150435.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.